Narrative
Researchers at the University of Manchester (UoM) have made a significant impact nationally and internationally on improving the outcome for children with acute lymphoblastic leukaemia (ALL) (~450 pa in the UK). The changes in clinical practice based on our research are now national standards of care for children with de novo and relapsed ALL in the UK and Ireland. Other international groups have adopted key findings from the results of our frontline trials. Our relapse protocol for childhood ALL underpins European and North American strategy for the management of relapsed disease.| Impact date | 2014 → 2019 |
|---|---|
| Category of impact | Health and wellbeing, Society and culture |
| Impact level | Adoption |
Research Beacons, Institutes and Platforms
- Cancer
- Manchester Cancer Research Centre
Documents & Links
Related content
-
Research output
-
Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: Results of the UK Medical Research Council ALL97 randomized trial
Research output: Contribution to journal › Article › peer-review
-
A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase
Research output: Contribution to journal › Article › peer-review
-
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study
Research output: Contribution to journal › Article › peer-review
-
Outcomes after induction failure in childhood acute lymphoblastic leukemia
Research output: Contribution to journal › Article › peer-review
-
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): An open-label randomised trial
Research output: Contribution to journal › Article › peer-review